-
1.发明公开公开(公告)号：US20240343790A1
公开(公告)日：2024-10-17
申请号：US18627131
申请日：2024-04-04
Applicant: Genzyme Corporation
Inventor： Huawei Qiu , Clark Pan , Julie Bird
CPC classification number: C07K16/22 , A61K39/395 , A61K39/3955 , C07K16/00 , C07K16/46 , C12N15/11 , C12N15/62 , A61K2039/505 , C07K2317/21 , C07K2317/35 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/64 , C07K2317/70 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/23 , C07K2319/73
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US11807690B2
公开(公告)日：2023-11-07
申请号：US16655500
申请日：2019-10-17
Applicant: Genzyme Corporation
Inventor： Clark Pan , Huawei Qiu , Pradeep Dhal , Bo Chen , Diego Gianolio
CPC classification number: C07K16/2893 , A61K47/549 , A61K47/6803 , A61K47/6869 , A61K47/6889 , C07K16/28 , C07K16/2809 , C07K16/2851 , C07K16/32 , C07K16/40 , C07K2317/40 , C07K2317/41 , C07K2317/522 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US20220363740A1
公开(公告)日：2022-11-17
申请号：US17713087
申请日：2022-04-04
Applicant: GENZYME CORPORATION
Inventor： Huawei Qiu , Clark Pan , Julie Bird
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US10508146B2
公开(公告)日：2019-12-17
申请号：US15555499
申请日：2016-03-03
Applicant: GENZYME CORPORATION
Inventor： Huawei Qiu , Clark Pan , Julie Bird
IPC: A61K39/395 , C07K16/22 , C07K16/46 , C07K16/00 , A61K39/00
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US10214589B2
公开(公告)日：2019-02-26
申请号：US15417648
申请日：2017-01-27
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
Patent Agency Ranking
公开(公告)号：US09790268B2
公开(公告)日：2017-10-17
申请号：US14205264
申请日：2014-03-11
Applicant: Genzyme Corporation
Inventor： Clark Pan , Huawei Qiu
CPC classification number: C07K16/18 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K47/6889 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K16/00 , C07K16/2809 , C07K16/2851 , C07K16/2893 , C07K16/32 , C07K16/40 , C07K2317/41 , C07K2317/52 , C07K2317/522 , C07K2317/71 , C07K2317/73
Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US20220089763A1
公开(公告)日：2022-03-24
申请号：US17404412
申请日：2021-08-17
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US11130816B2
公开(公告)日：2021-09-28
申请号：US16238932
申请日：2019-01-03
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US20250066497A1
公开(公告)日：2025-02-27
申请号：US18787702
申请日：2024-07-29
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
公开(公告)号：US12110338B2
公开(公告)日：2024-10-08
申请号：US17404412
申请日：2021-08-17
Applicant: Genzyme Corporation
Inventor： Clark Pan , Qun Zhou , James Stefano , Pradeep Dhal , Bo Chen , Diego Gianolio , Robert Miller , Huawei Qiu
CPC classification number: C07K16/2893 , A61K47/549 , A61K47/6803 , A61K47/6869 , A61K47/6889 , C07K16/28 , C07K16/2809 , C07K16/2851 , C07K16/32 , C07K16/40 , C07K2317/40 , C07K2317/41 , C07K2317/522 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.018 seconds)
